Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.

Background When a clinical treatment fails or shows suboptimal results, the question of when to switch to another treatment arises. Treatment switching strategies are often dynamic because the time of switching depends on the evolution of an individual's time-varying covariates. Dynamic strategies can be directly compared in randomized trials. For example, HIV-infected individuals receiving antiretroviral therapy could be randomized to switching therapy within 90 days of HIV-1 RNA crossing above a threshold of either 400 copies/ml (tight-control strategy) or 1000 copies/ml (loose-control strategy). Methods We review an approach to emulate a randomized trial of dynamic switching strategies using observational data from the Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collaboration. We estimated the comparative effect of tight-control vs. loose-control strategies on death and AIDS or death via inverse-probability weighting. Results Of 43 803 individuals who initiated an eligible antiretroviral therapy regimen in 2002 or later, 2001 met the baseline inclusion criteria for the mortality analysis and 1641 for the AIDS or death analysis. There were 21 deaths and 33 AIDS or death events in the tight-control group, and 28 deaths and 41 AIDS or death events in the loose-control group. Compared with tight control, the adjusted hazard ratios (95% confidence interval) for loose control were 1.10 (0.73, 1.66) for death, and 1.04 (0.86, 1.27) for AIDS or death. Conclusions Although our effective sample sizes were small and our estimates imprecise, the described methodological approach can serve as an example for future analyses.

[1]  Stacey A. Kenfield,et al.  Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. , 2015, European journal of cancer.

[2]  Miguel A Hernán,et al.  The hazards of hazard ratios. , 2010, Epidemiology.

[3]  Mark J van der Laan,et al.  Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification , 2008, AIDS.

[4]  Richard D Moore,et al.  Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. , 2008, International journal of epidemiology.

[5]  James M Robins,et al.  The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals , 2010, AIDS.

[6]  M. Robins James,et al.  Estimation of the causal effects of time-varying exposures , 2008 .

[7]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[8]  Douglas D. Richman,et al.  Antiretroviral Treatment of Adult HIV Infection , 2008 .

[9]  M. Hernán,et al.  Evaluation of the Duplication of Staging CT Scans for Localized Colon Cancer in a Medicare Population , 2014, Medical care.

[10]  James M. Robins,et al.  The International Journal of Biostatistics CAUSAL INFERENCE When to Start Treatment ? A Systematic Approach to the Comparison of Dynamic Regimes Using Observational Data , 2011 .

[11]  J. Robins A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect , 1986 .

[12]  J.,et al.  The New England Journal of Medicine , 2012 .

[13]  James M. Robins,et al.  Observational Studies Analyzed Like Randomized Experiments: An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease , 2008, Epidemiology.

[14]  M. Hernán,et al.  Comparative Effectiveness of Two Anemia Management Strategies for Complex Elderly Dialysis Patients , 2014, Medical care.

[15]  C. Leen,et al.  British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.) , 2014, HIV medicine.

[16]  C. Leen,et al.  British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2015 , 2016, HIV medicine.

[17]  Eoin Coakley,et al.  Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[19]  James M. Robins,et al.  Comparative Effectiveness of Dynamic Treatment Regimes: An Application of the Parametric G-Formula , 2011, Statistics in biosciences.

[20]  Jennifer F Hoy,et al.  Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. , 2014, JAMA.

[21]  James M Robins,et al.  The International Journal of Biostatistics CAUSAL INFERENCE Dynamic Regime Marginal Structural Mean Models for Estimation of Optimal Dynamic Treatment Regimes , Part II : Proofs of Results , 2011 .

[22]  W. A. Thompson,et al.  On the treatment of grouped observations in life studies. , 1977, Biometrics.

[23]  M. J. van der Laan,et al.  The International Journal of Biostatistics Causal Effect Models for Realistic Individualized Treatment and Intention to Treat Rules , 2011 .

[24]  J. Robins,et al.  The International Journal of Biostatistics CAUSAL INFERENCE Dynamic Regime Marginal Structural Mean Models for Estimation of Optimal Dynamic Treatment Regimes , Part I : Main Content , 2011 .

[25]  R. Little,et al.  The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.

[26]  J. Robins,et al.  Comparison of dynamic treatment regimes via inverse probability weighting. , 2006, Basic & clinical pharmacology & toxicology.

[27]  Brent A. Johnson,et al.  Modeling Clinical Endpoints as a Function of Time of Switch to Second‐Line ART with Incomplete Data on Switching Times , 2013, Biometrics.

[28]  Uwe Siebert,et al.  Effects of multiple interventions , 2004 .

[29]  Roger Logan,et al.  Observational data for comparative effectiveness research: An emulation of randomised trials of statins and primary prevention of coronary heart disease , 2013, Statistical methods in medical research.

[30]  J. Sterne,et al.  Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). , 2014, International journal of epidemiology.

[31]  Stephen R Cole,et al.  Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.

[32]  Brent A. Johnson,et al.  Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095 , 2012, Journal of the American Statistical Association.

[33]  J. Robins,et al.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.

[34]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .